
B3 Bio Inc Profile last edited on: 10/5/16
CAGE: 55RB8
UEI:
Business Identifier: RNA oligonucleotide based drugs Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 04
County: Durham
Congr. District: 04
County: Durham
Public Profile
b3bio is a privately-held biotechnology company with an expertise in the field of RNA therapeutics. The companyâs technology platform, which is licensed from Duke University and the University of Texas, is aimed at developing an entirely new class of medicines which employ small RNA molecules to target individual cells and tissues with remarkable precisio
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2010 | 1 | NIH | $183,938 | |
Project Title: Modular Internalizing Molecules For Treatment Of More Than One Stage Of Malignanc |
Key People / Management
Dani P Bolognesi -- CEO & Chairman
Robert Bonczek -- Chief Financial Officer Co-Founder
Michael L Greenberg -- Head of Research & Development
Robert Bonczek -- Chief Financial Officer Co-Founder
Michael L Greenberg -- Head of Research & Development
Company News
There are no news available.